A drug discovery consortium led by Novartis, Swiss TPH and the University of Glasgow has discovered a new class of compounds that effectively inhibit the growth of trypanosomes.
A drug discovery consortium led by Novartis, Swiss TPH and the University of Glasgow has discovered a new class of compounds that effectively inhibit the growth of trypanosomes. Scientists have identified a new class of compounds called cyanotriazoles that have the potential to effectively inhibit the growth of trypanosomes, the parasites responsible for Chagas disease and African sleeping sickness. The results, published yesterday in the journal Science, demonstrate that the compounds show no toxicity to human cells, raising hopes for the development of new and improved treatments for neglected tropical diseases. Chagas disease and human African trypanosomiasis (HAT), also known as African sleeping sickness, are significant global health challenges, particularly in Latin America and sub-Saharan Africa where millions of people are at risk. These neglected tropical diseases primarily affect impoverished communities and can be fatal if left untreated. Current treatments for Chagas disease in particular are poorly tolerated, require lengthy regimens, and come with safety concerns, leaving patients vulnerable to severe complications. A drug discovery consortium led by Novartis, the Swiss Tropical and Public Health Institute (Swiss TPH) and the University of Glasgow has discovered a new class of compounds called cyanotriazoles (CTs) that effectively inhibit the growth of trypanosomes, the parasites responsible for Chagas disease and African sleeping sickness.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
